Pharmacotherapy for borderline personality disorder: NICE guideline
Authors:
- Tim KendallTKTim Kendall
- Rachel BurbeckRBRachel Burbeck
- Anthony BatemanABAnthony Bateman
- 1 February 2010
- journal article
- letter
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 196 (2) , 158-159
Abstract
There are a number of reasons for the disparity. First, we did not consider the evidence from some studies to be usable.3–7 These trials tended to find large effect sizes favouring treatment compared with effect sizes from other trials. Following further investigation, we considered this evidence for topiramate, lamotrigine or aripiprazole to be unreliable and excluded the trials from our analysis (see p. 218 of the full guideline2).Keywords
This publication has 9 references indexed in Scilit:
- Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trialsThe British Journal of Psychiatry, 2010
- Aripiprazole in the Treatment of Patients With Borderline Personality Disorder: A Double-Blind, Placebo-Controlled StudyAmerican Journal of Psychiatry, 2006
- Aripiprazole in the Treatment of Patients With Borderline Personality Disorder: A Double-Blind, Placebo-Controlled StudyAmerican Journal of Psychiatry, 2006
- Topiramate Treatment for Women With Borderline Personality DisorderJournal of Clinical Psychopharmacology, 2006
- Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled studyJournal of Psychopharmacology, 2005
- Treatment of aggression with topiramate in male borderline patients: A double-blind, placebo-controlled studyBiological Psychiatry, 2005
- Topiramate Treatment of Aggression in Female Borderline Personality Disorder PatientsThe Journal of Clinical Psychiatry, 2004
- Empirical Evidence and Psychotherapy: A Growing Scientific BaseAmerican Journal of Psychiatry, 2001
- The prevention of recurrent suicidal acts.British Journal of Clinical Pharmacology, 1983